Bertrand Knebelmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10744759/publications.pdf

Version: 2024-02-01

65 papers	5,272 citations	94433 37 h-index	98798 67 g-index
70 all docs	70 docs citations	70 times ranked	5284 citing authors

#	Article	IF	Citations
1	X-linked Alport Syndrome. Journal of the American Society of Nephrology: JASN, 2000, 11, 649-657.	6.1	455
2	X-Linked Alport Syndrome. Journal of the American Society of Nephrology: JASN, 2003, 14, 2603-2610.	6.1	394
3	Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. Journal of Clinical Investigation, 2010, 120, 4065-4076.	8.2	310
4	Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney International, 2012, 81, 494-501.	5.2	275
5	Spectrum of HNF1B Mutations in a Large Cohort of Patients Who Harbor Renal Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1079-1090.	4.5	236
6	Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet, The, 2015, 385, 1993-2002.	13.7	227
7	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 2016, 31, 337-348.	0.7	206
8	Cyst Infections in Patients with Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1183-1189.	4.5	186
9	Autosomal recessive Alport syndrome: Immunohistochemical study of type IV collagen chain distribution. Kidney International, 1995, 47, 1142-1147.	5.2	155
10	Rituximab in Severe Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 579-587.	4.5	151
11	Improving Mutation Screening in Familial Hematuric Nephropathies through Next Generation Sequencing. Journal of the American Society of Nephrology: JASN, 2014, 25, 2740-2751.	6.1	130
12	Evidence of digenic inheritance in Alport syndrome. Journal of Medical Genetics, 2015, 52, 163-174.	3.2	129
13	Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy. JAMA - Journal of the American Medical Association, 2017, 318, 2099.	7.4	120
14	Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatric Nephrology, 2013, 28, 5-11.	1.7	118
15	Splice-mediated insertion of an Alu sequence in the COL4A3 mRNA causing autosomal recessive Alport syndrome. Human Molecular Genetics, 1995, 4, 675-679.	2.9	114
16	Phenotype and Genotype Characterization of Adenine Phosphoribosyltransferase Deficiency. Journal of the American Society of Nephrology: JASN, 2010, 21, 679-688.	6.1	112
17	Phenotype and Outcome in Hereditary Tubulointerstitial Nephritis Secondary to UMOD Mutations. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2429-2438.	4.5	109
18	Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney International, 2015, 88, 1135-1143.	5.2	104

#	Article	IF	Citations
19	Clinical and Genetic Spectrum of Bartter Syndrome Type 3. Journal of the American Society of Nephrology: JASN, 2017, 28, 2540-2552.	6.1	92
20	Alport syndrome and diffuse leiomyomatosis: Deletions in the 5â€² end of the COL4A5 collagen gene. Kidney International, 1992, 42, 1178-1183.	5.2	91
21	Endoplasmic reticulum stress drives proteinuria-induced kidney lesions via Lipocalin 2. Nature Communications, 2016, 7, 10330.	12.8	88
22	Adenine Phosphoribosyltransferase Deficiency. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1521-1527.	4.5	87
23	Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood, 2019, 133, 576-587.	1.4	78
24	Multiplex epithelium dysfunction due to CLDN10 mutation: the HELIX syndrome. Genetics in Medicine, 2018, 20, 190-201.	2.4	75
25	CKD and Its Risk Factors among Patients with Cystinuria. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 842-851.	4.5	71
26	Observations of a large Dent disease cohort. Kidney International, 2016, 90, 430-439.	5.2	71
27	Mutation Update of theCLCN5Gene Responsible for Dent Disease 1. Human Mutation, 2015, 36, 743-752.	2.5	66
28	Cystine crystal volume determination: a useful tool in the management of cystinuric patients. Urological Research, 2003, 31, 207-211.	1.5	58
29	Î²4 Integrin and Laminin 5 Are Aberrantly Expressed in Polycystic Kidney Disease. American Journal of Pathology, 2003, 163, 1791-1800.	3.8	58
30	Rapamycin inhibits human renal epithelial cell proliferation: Effect on cyclin D3 mRNA expression and stability. Kidney International, 2005, 67, 2422-2433.	5.2	58
31	Cystinuria: clinical practice recommendation. Kidney International, 2021, 99, 48-58.	5.2	58
32	Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective. Kidney International, 2018, 93, 716-726.	5.2	46
33	Defects in KCNJ16 Cause a Novel Tubulopathy with Hypokalemia, Salt Wasting, Disturbed Acid-Base Homeostasis, and Sensorineural Deafness. Journal of the American Society of Nephrology: JASN, 2021, 32, 1498-1512.	6.1	46
34	Thalidomide in patients with multiple myeloma and renal failure. British Journal of Haematology, 2004, 125, 96-97.	2.5	45
35	mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases. Kidney International, 2019, 95, 455-466.	5.2	44
36	The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. Kidney International, 2017, 91, 720-728.	5.2	43

#	Article	IF	Citations
37	Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood, 2020, 135, 1833-1846.	1.4	42
38	Laminin 5 Regulates Polycystic Kidney Cell Proliferation and Cyst Formation. Journal of Biological Chemistry, 2006, 281, 29181-29189.	3.4	40
39	A New Workflow for Proteomic Analysis of Urinary Exosomes and Assessment in Cystinuria Patients. Journal of Proteome Research, 2015, 14, 567-577.	3.7	39
40	Aberrant splicing of the COL4A5 gene in patients with Alport syndrome. Human Molecular Genetics, 1994, 3, 317-322.	2.9	37
41	Impaired formation of desmosomal junctions in ADPKD epithelia. Histochemistry and Cell Biology, 2005, 124, 487-497.	1.7	35
42	Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. American Journal of Nephrology, 2021, 52, 180-189.	3.1	31
43	Adverse events associated with currently used medical treatments for cystinuria and treatment goals: results from a series of 442 patients in France. BJU International, 2019, 124, 849-861.	2.5	30
44	An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes. Kidney International, 2020, 98, 1589-1604.	5.2	27
45	Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease. Clinical Genetics, 2022, 101, 390-402.	2.0	26
46	Complete Remission of Lupus Nephritis With Rituximab and Steroids for Induction and Rituximab Alone for Maintenance Therapy. American Journal of Kidney Diseases, 2008, 52, 346-352.	1.9	25
47	Clinical and molecular characterization of cystinuria in a French cohort: relevance of assessing largeâ€scale rearrangements and splicing variants. Molecular Genetics & Genomic Medicine, 2017, 5, 373-389.	1.2	22
48	A molecular approach to inherited kidney disorders. Kidney International, 1993, 44, 1205-1216.	5.2	21
49	Screening for Unruptured Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Survey of 420 Nephrologists. PLoS ONE, 2016, 11, e0153176.	2.5	17
50	COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. Nephrology Dialysis Transplantation, 2022, 37, 1357-1365.	0.7	17
51	2,8-Dihydroxyadenine Urolithiasis: A Not So Rare Inborn Error of Purine Metabolism. Nucleosides, Nucleotides and Nucleic Acids, 2014, 33, 241-252.	1.1	16
52	Mesangial IgG Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2002, 13, 379-387.	6.1	15
53	Light and heavy chain deposition disease associated with CH1 deletion. CKJ: Clinical Kidney Journal, 2015, 8, 237-239.	2.9	12
54	APOL1 risk genotype in European steroid-resistant nephrotic syndrome and/or focal segmental glomerulosclerosis patients of different African ancestries. Nephrology Dialysis Transplantation, 2019, 34, 1885-1893.	0.7	12

#	Article	IF	Citations
55	The 2019 and 2021 International Workshops on Alport Syndrome. European Journal of Human Genetics, 2022, 30, 507-516.	2.8	12
56	Red Blood Cell AE1/Band 3 Transports in Dominant Distal Renal Tubular Acidosis Patients. Kidney International Reports, 2020, 5, 348-357.	0.8	11
57	Kidney Transplant Outcomes in Patients With Adenine Phosphoribosyltransferase Deficiency. Transplantation, 2020, 104, 2120-2128.	1.0	10
58	Reversible paraparesis in multiple myeloma with renal failure. Nephrology Dialysis Transplantation, 2006, 21, 1439-1440.	0.7	4
59	Enzyme therapy for Fabry's disease: registered for success?. Lancet, The, 2009, 374, 1950-1951.	13.7	3
60	Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report. CKJ: Clinical Kidney Journal, 2022, 15, 407-416.	2.9	3
61	Erythrocytosis associated with IgA nephropathy. EBioMedicine, 2022, 75, 103785.	6.1	2
62	AA amyloidosis associated with Fabry disease. International Journal of Clinical Practice, 2020, 74, e13577.	1.7	1
63	FC 0104-WEEK ANTIBIOTIC THERAPY PREVENTS RECURRENT RENAL CYST INFECTIONS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
64	Genetic Diagnosis and Counseling in Inherited Renal Diseases. , 1998, , 685-694.		0
65	Efficacy of Prolonged Antibiotic Therapy for Renal Cyst Infections in Polycystic Kidney Disease. Mayo Clinic Proceedings, 2022, 97, 1305-1317.	3.0	0